Inogen opened lower at $5.73, compared with its previous close of $5.75. In the last trading session, the stock traded between $5.61 and $5.91. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Inogen is now worth
$ 16.17
Resulting in a loss of
$ 83.83 (83.83%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.12 (-2.12%)
Day High
$5.91
Day Low
$5.61
Day Open
$5.73
Prev Close
$5.75
Volume
1,51,472
1W Return
-21.91%
1M Return
-12.17%
3M Return
-4.74%
6M Return
-14.98%
1Y Return
-19.48%
Fundamentals
Market Cap ($ Mn)
146
PE Ratio
-
PB Ratio
0.84
PEG Ratio
-
ROE
-11.84%
ROCE
-11.72%
EPS (TTM)
$-0.62
Investment Returns
1 Week
-21.91%
1 Month
-12.17%
3 Months
-4.74%
6 Months
-14.98%
9 Months
-8.19%
Financials
Quarterly
All values in $ Mn
92.3
Jun 25
92.4
Sep 25
81.7
Dec 25
85.1
Mar 26
0.0
Mar 26
77.2
Sep 26
Updates
6Nov
Inogen Q3FY26 Results: Revenue falls 2.4% to $77.2M as US sales grow
Total revenue fell 2.4% YoY to $77.2 million, while U.S. sales grew 3.8% to $42.2 million. Completed divestiture of U.S. Oxygen rental business for $24.8 million to streamline operations. Announced $20 million annualized cost savings program by end-2027, with $10 million targeted for 2026. Adjusted net loss from continuing operations was $0.4 million; GAAP loss included $10.6 million goodwill impairment. Q4FY26 revenue guidance set at $65 million to $68 million, expecting U.S. growth to offset international softness.
7 days ago
15Oct
Inogen to report Q3FY26 results on November 5, 2026
Inogen to report Q3FY26 financial results on November 5, 2026. Conference call scheduled for 5:00 pm Eastern Time. Replay available until November 12, 2026.
28 days ago
13Oct
Inogen Q2 FY26 revenue up 3% to $95.1M; EBITDA rises 15%
Revenue rose 3% YoY to $95.1 million, driven by 15% international growth. Adjusted EBITDA increased 15% to $2.4 million amid cost discipline. Full-year revenue guidance lowered to $355-$361 million due to channel shifts. U.S. sales declined 2% as B2B growth offset D2C and rental declines. Company holds $107 million in cash with no outstanding debt.
1mo ago
1Oct
Inogen sells US rental unit to Rotech for up to $25 million
Inogen divests U.S. oxygen rental business to Rotech Healthcare for up to $25 million. Transaction expected to close in Q4 2026 with long-term supply agreement included. Rental segment revenue fell 9.8% YoY to $24.3 million in H1 2026. Board approves $15 million increase in share repurchase authorization to $45 million total.
1mo ago
7Aug
Inogen cuts FY26 sales guidance to $355M-$361M
Inogen lowers FY26 sales guidance to $355.000M-$361.000M from $366.000M-$373.000M. The new range falls below the $369.267M analyst estimate, indicating potential revenue shortfalls.
3mo ago
7Aug
Inogen Q3 Results: Sales miss $98.967M estimate
Inogen's Q3 sales of $92.400 million missed the $98.967 million analyst estimate. The revenue shortfall marks a deviation from market expectations for the quarter.
